MKSIMKS Inc.

$264.42+106% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is the business good?

Good

A genuinely good business: earnings fully cash-backed (1.0×) and margins widening.

2 good, 2 neutral
Fundamental health (F-score)6 / 9SEC EDGAR · Dec 31, 2025

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.03×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years+50.8 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from4% ROA

A balanced mix of margins, efficiency, and leverage. ROE 12% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market
Leverage (Debt/EBITDA)middle of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is MKSI?

MKS Inc. earns 8.3% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.

8.3%

Return on invested capital · cost of capital 9.0% · 0.69 points below what the capital costs: growth destroys value

Operating margin
16%

Operating margin · Scientific & Technical Instruments median 16% · 12 months to Q2 2026

Cash conversion
1.03×

Cash conversion · 1.28× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
+7.9%

Share count, year on year · shareholders own a smaller slice than a year ago

Operating margin by fiscal year
YearOperating margin
FY202019%
FY202124%
FY202217%
FY2023−43%
FY202414%
FY202513%
Details›
Gross margin12 months to Q2 2026
47%
Operating margin12 months to Q2 2026
16%
Net margin12 months to Q2 2026
10%
Free cash flow margin
10%
R&D as % of revenue
7.1%
Revenue, trailing twelve months
$4.35B
Free cash flow, trailing twelve months
$455M
Net income, trailing twelve months
$440M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
8.3%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.